What question did this study set out to answer?

To establish and validate a rabbit model of chronic daunorubicin-induced cardiomyopathy and heart failure, and to evaluate the cardioprotective efficacy of dexrazoxane.

December 10, 2003European Journal of Heart Failure

Rabbit Model for in Vivo Study of Anthracycline-Induced Heart Failure and for the Evaluation of Protective Agents

View Full Paper

Ask AI

Bookmark

Why the study?

Does dexrazoxane prevent daunorubicin-induced heart failure in a rabbit model?

Key Points

To establish and validate a rabbit model of chronic daunorubicin-induced cardiomyopathy and heart failure, and to evaluate the cardioprotective efficacy of dexrazoxane.
Rabbits were assigned to three weekly regimens for 10 weeks: saline controls (n=10), daunorubicin (3 mg/kg i.v., n=11), or dexrazoxane (60 mg/kg i.p.) administered 30 minutes prior to daunorubicin (n=5).
Heart damage was quantitated via histopathology, invasive hemodynamics (dP/dt(max), dP/dt(min)), non-invasive systolic function (left ventricular ejection fraction, PEP/LVET index), and plasma cardiac troponin T levels.
Repeated daunorubicin administration induced pronounced myocardial impairment, resulting in both systolic and diastolic heart failure across all hemodynamic, functional, and biochemical evaluations.
Pretreatment with dexrazoxane significantly reduced daunorubicin-induced cardiotoxicity, while other systemic toxicities remained within an acceptable range.

Structured PICO

Does dexrazoxane prevent daunorubicin-induced heart failure in a rabbit model?

Population

26 rabbits

Intervention

Daunorubicin (3 mg/kg i.v.) with or without dexrazoxane (60 mg/kg i.p. 30 min prior), administered once weekly for 10 weeks

Comparator

i.v. saline once weekly for 10 weeks

Outcome

Heart damage and protective action measured by histopathology, invasive haemodynamics (dP/dt max, dP/dt min), non-invasive systolic function (LVEF, PEP/LVET index), and cardiac troponin T plasma concentrationssurrogate

The rabbit model of daunorubicin-induced cardiotoxicity is a reliable preclinical model for evaluating heart failure and potential cardioprotective agents like dexrazoxane.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports rabbit model validation for anthracycline cardiotoxicity; leaves open clinical translation of dexrazoxane cardioprotection.

Cite This Study

Šimůnek et al. (2003) studied this question.

synapsesocial.com/papers/6a76e91e6789de8d0af6e489 https://doi.org/10.1016/j.ejheart.2003.05.003

Topics

HFrEF treatment Heart failure Echocardiography

View Full Paper

Ask AI

Bookmark

Rabbit Model for in Vivo Study of Anthracycline-Induced Heart Failure and for the Evaluation of Protective Agents

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Rabbit Model for in Vivo Study of Anthracycline-Induced Heart Failure and for the Evaluation of Protective Agents

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider